Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, 22 S. Greene St, Baltimore, MD, 21201, USA.
Department of Medicine, Tufts University School of Medicine, Washington St, Boston, MA, 02111, USA.
Hepatol Int. 2022 Dec;16(6):1448-1457. doi: 10.1007/s12072-022-10414-8. Epub 2022 Sep 11.
The presence of perioperative diabetes may lead to increased mortality risks following liver transplant (LT) in patients with non-alcoholic steatohepatitis (NASH). This risk factor was evaluated using a UNOS-STAR national database.
The UNOS-STAR liver transplant registry 2005-2019 was used to select patients with NASH (including cryptogenic liver disease). The following populations were excluded: those younger than 18 years old and those with living donors/dual transplants. Selected patients were stratified into those with and without pre-LT diabetes and compared to the individual mortality endpoints using iterative Cox analyses.
6324 recipients with and 8251 without diabetes were selected. The median follow-up time was 3.07 years. Those with diabetes were older (58.50 vs. 54.50 years, p < 0.001), were more likely to be Hispanic or Asian, and had higher BMI than the non-diabetics (31.10 vs. 29.70 kg/m p < 0.001); however, there was no difference in gender (female 41.9 vs. 43.1% p = 0.170). Compared to non-diabetics, recipients with diabetes had a higher rate of all-cause mortality (61.68 vs. 47.80 per 1000 person-years). In multivariate iterations, pre-LT diabetes was associated with all-cause mortality (aHR 1.19 95% CI 1.11-1.27) as well as deaths due to cardiac (p = 0.014 aHR 1.24 95% CI 1.04-1.46) and renal causes (p = 0.039 aHR 1.38 95% CI 1.02-1.87).
The presence of pre-LT diabetes is associated with all-cause mortality and deaths due to cardiac and renal causes following LT. The findings warrant an early preoperative screening procedure to ensure that patients with diabetes have their metabolic risk factors optimized prior to LT.
围手术期糖尿病可能会增加非酒精性脂肪性肝炎(NASH)患者肝移植(LT)后的死亡风险。本研究使用 UNOS-STAR 国家数据库对这一风险因素进行了评估。
使用 UNOS-STAR 肝移植登记处 2005-2019 年的数据选择 NASH(包括隐源性肝病)患者。排除年龄小于 18 岁和活体供体/双移植患者。将选定的患者分为 LT 前有糖尿病和无糖尿病的两组,并使用迭代 Cox 分析比较个体死亡终点。
纳入 6324 例有糖尿病和 8251 例无糖尿病的患者。中位随访时间为 3.07 年。糖尿病组患者年龄更大(58.50 岁 vs. 54.50 岁,p<0.001),更有可能为西班牙裔或亚裔,且 BMI 高于非糖尿病组(31.10 公斤/米 vs. 29.70 公斤/米,p<0.001);但两组间的性别比例无差异(女性分别为 41.9%和 43.1%,p=0.170)。与非糖尿病组相比,糖尿病组患者的全因死亡率更高(61.68 例/1000 人年 vs. 47.80 例/1000 人年)。在多变量迭代中,LT 前糖尿病与全因死亡率(aHR 1.19,95%CI 1.11-1.27)以及心源性(p=0.014,aHR 1.24,95%CI 1.04-1.46)和肾源性(p=0.039,aHR 1.38,95%CI 1.02-1.87)死亡率相关。
LT 前糖尿病与 LT 后全因死亡率以及心源性和肾源性死亡率相关。这些发现提示应进行术前早期筛查,以确保糖尿病患者在 LT 前优化其代谢危险因素。